Effect of Ruxolitinib (RUX) on plaque formation of a selection of viruses.

<p>(a) RSV WT and derivatives with deleted IFN antagonists NS1 (ΔNS1) and NS2 (ΔNS2). RSV plaques were grown in the MRC5 cell-line or derivative constitutively expressing PIV5-V, fixed on the days indicated and visualized by immunostaining with an anti-RSV F protein antibody. (b) Influenza (A/PR/8/34) WT and derivative with a deleted IFN antagonist NS1 (ΔNS1). Influenza plaques were grown in the MDCK cell-line, fixed on the days indicated and visualized by immunostaining with an anti-influenza X31 antibody. (c) MeV Edmonston (Edm) and MuV Enders (End) live-attenuated vaccine strains. MeV and MuV plaques were grown in MRC5 cell-line or derivative constitutively expressing PIV5-V fixed on the day indicated and visualized by immunostaining with an anti-MeV NP or anti-MuV NP antibodies respectively. RUX was used at 4 µM and compared with the equivalent volume of DMSO.